BACE1 and Alzheimer disease: Despite normalization of BACE1 levels to synaptic markers in AD brain, it remains difficult to determine from postmortem brain whether a specific change is an epiphenomenon in late-stage AD, or whether it is an early event directly involved in pathogenesis.